AU556326B2 - Vaccine for fluetonge disease employing platinum compounds - Google Patents

Vaccine for fluetonge disease employing platinum compounds

Info

Publication number
AU556326B2
AU556326B2 AU15426/83A AU1542683A AU556326B2 AU 556326 B2 AU556326 B2 AU 556326B2 AU 15426/83 A AU15426/83 A AU 15426/83A AU 1542683 A AU1542683 A AU 1542683A AU 556326 B2 AU556326 B2 AU 556326B2
Authority
AU
Australia
Prior art keywords
fluetonge
vaccine
platinum compounds
employing platinum
disease employing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU15426/83A
Other versions
AU1542683A (en
Inventor
Jarue S. Manning
Giorgio Poli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU1542683A publication Critical patent/AU1542683A/en
Application granted granted Critical
Publication of AU556326B2 publication Critical patent/AU556326B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12161—Methods of inactivation or attenuation
    • C12N2720/12163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/814—Viral vaccine for ovine species, e.g. sheep

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU15426/83A 1982-06-08 1983-06-07 Vaccine for fluetonge disease employing platinum compounds Ceased AU556326B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/386,469 US4645666A (en) 1982-06-08 1982-06-08 Vaccine for bluetongue disease employing platinum compounds
US386469 1982-06-08

Publications (2)

Publication Number Publication Date
AU1542683A AU1542683A (en) 1983-12-22
AU556326B2 true AU556326B2 (en) 1986-10-30

Family

ID=23525714

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15426/83A Ceased AU556326B2 (en) 1982-06-08 1983-06-07 Vaccine for fluetonge disease employing platinum compounds

Country Status (5)

Country Link
US (1) US4645666A (en)
EP (1) EP0097003A3 (en)
AU (1) AU556326B2 (en)
CA (1) CA1214724A (en)
NZ (1) NZ204437A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839298A (en) * 1986-02-14 1989-06-13 Akzo N.V. Virus inactivating diluents used in immunoassays
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US8420072B2 (en) * 2011-03-24 2013-04-16 The United States Of America, As Represented By The Secretary Of Agriculture Vaccination of sex reversed hybrid tilapia (Oreochromis niloticus x O. aureus) with an inactivated Vibrio vulnificus vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847737A (en) * 1965-03-22 1974-11-12 A Kanarek Inactivation of myxoviruses and method of preparing a vaccine therefrom
US4053587A (en) * 1973-04-13 1977-10-11 Research Corporation Method of treating viral infections
GB1585203A (en) * 1978-02-27 1981-02-25 Research Corp Complex or salt of a platinum compound and a nitrogen containing polymer
US4273755A (en) * 1979-08-16 1981-06-16 Mpd Technology Corporation Preparation of platinum complexes
FR2483779A1 (en) * 1980-06-05 1981-12-11 Synthelabo PROCESS FOR ISOLATING VIRAL GLYCOPROTETIC ANTIGENS AND APPLICATION THEREOF TO VACCINE PREPARATION
DE3033932C2 (en) * 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the cold sterilization of preparations containing blood coagulation factor VIII

Also Published As

Publication number Publication date
CA1214724A (en) 1986-12-02
US4645666A (en) 1987-02-24
EP0097003A2 (en) 1983-12-28
EP0097003A3 (en) 1986-03-12
NZ204437A (en) 1986-04-11
AU1542683A (en) 1983-12-22

Similar Documents

Publication Publication Date Title
IT1155369B (en) PROCEDURE FOR PREPARING ZEOLITHIC ADSORBENTS WITHOUT BINDER
AU552911B2 (en) Infaltable packer
AU566510B2 (en) Pharmaceutical 1,4-benzodiazepine-2-ones
AU557693B2 (en) Pharmaceutical sustained release compounds
ZA826418B (en) 4a-substituted avermectin compounds
AU560073B2 (en) Spergualin-related compounds
AU8420482A (en) Zwitter-cephem compounds
AU2045783A (en) Thermostat
ES542138A0 (en) PROCEDURE FOR PREPARING OXIMA O-SUBSTITUTED COMPOUNDS
AU606630B2 (en) Acetylcinnamate compounds
AU561449B2 (en) Pharmaceutical 3-aryl-7-chloro-9-oxo-3,4-dihyroacridines
AU1425983A (en) Pyrazopyridine compounds
AU8030582A (en) Novel compounds
IT1203702B (en) MEN-MEN HYBRIDOMES FOR CERVICAL CARCINOMES
GB8305175D0 (en) Substituted thiopyranopyrimidine pharmaceutical compounds
GB8332269D0 (en) Pharmaceutical compounds
AU553154B2 (en) Iron-selenium preparation
AU1818083A (en) Medicinal n-imidazolylalkylbenzamides
AU566485B2 (en) Piperidine compounds
RO85392A (en) PROCEDURE FOR PREPARATION & HALOALCHILAMIDE
AU556326B2 (en) Vaccine for fluetonge disease employing platinum compounds
AU553665B2 (en) 2-beta-d-ribofuranosylselenazole-4-carboxamide compounds
AU7121281A (en) Chlamydous vaccine
AU1777983A (en) Anesthetic-antipruritic compounds
GB2137202B (en) Novel pharmaceutical compounds